Gefitinib: Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

added blog Health

2025-02-25 07:12:59 -

Lung cancer remains one of the most prevalent and deadly cancers worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Among NSCLC patients, mutations in the epidermal growth factor receptor (EGFR) gene have been identified as a key driver of tumor growth. Gefitinib, an oral tyrosine kinase inhibitor (TKI), has emerged as a revolutionary treatment for...

0 Comments 0 Shares 142 Views 0 Reviews